{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:11:24Z","timestamp":1794852684565,"version":"4.9.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>The most common neuroendocrine tumor in the urinary bladder is small cell carcinoma, which can be pure or mixed with components of urothelial or other histologic subtypes. Large cell neuroendocrine carcinoma of the bladder is rare and remains ill-defined but is increasingly recognized. Well-differentiated neuroendocrine tumor and paraganglioma can arise in the bladder but are very rare in this location. Recent advances in molecular characterization allowed for better classification and may offer improved stratification of these tumors.<\/jats:p>","DOI":"10.1097\/pap.0000000000000433","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T04:00:55Z","timestamp":1711339255000},"page":"169-177","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Updates on Urinary Bladder Tumors With Neuroendocrine Features"],"prefix":"10.1097","volume":"31","author":[{"given":"Dilara","family":"Akbulut","sequence":"first","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: Divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12022-016-9444-5","article-title":"Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization Classification: Molecular and clinical characteristics","volume":"27","author":"Kouba","year":"2016","journal-title":"Endocr Pathol"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/PAT.0000000000000301","article-title":"High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: A series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma","volume":"47","author":"Gupta","year":"2015","journal-title":"Pathology"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/PAS.0000000000001740","article-title":"Urinary large cell neuroendocrine carcinoma: A clinicopathologic analysis of 22 Cases","volume":"45","author":"Wang","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","article-title":"Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy","volume":"20","author":"Teo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/1097-0142(196905)23:5<1110::AID-CNCR2820230515>3.0.CO;2-C","article-title":"Pheochromocytoma of the urinary bladder","volume":"23","author":"Albores-Saavedra","year":"1969","journal-title":"Cancer"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/1097-0142(1971)28:4<1063::AID-CNCR2820280433>3.0.CO;2-R","article-title":"Paraganglioma of the urinary bladder","volume":"28","author":"Leestma","year":"1971","journal-title":"Cancer"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.5858\/2003-127-e22-CTOTU","article-title":"Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature","volume":"127","author":"Martignoni","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0b013e318208f96a","article-title":"Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases","volume":"35","author":"Chen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"R12-20250615","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"key":"R13-20250615","first-page":"1016","article-title":"Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder","volume":"11","author":"Hailemariam","year":"1998","journal-title":"Mod Pathol"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-8-19","article-title":"Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report","volume":"8","author":"Colarossi","year":"2013","journal-title":"Diagn Pathol"},{"key":"R15-20250615","first-page":"739","article-title":"Pathological, clinical and molecular characterization of large cell neuroendocrine carcinoma (LCNEC) of the urinary tract","volume":"103","author":"Gandhi","year":"2023","journal-title":"Laboratory Investigation"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/PAP.0b013e3180ca8a89","article-title":"Neuroendocrine lesions of the genitourinary tract","volume":"14","author":"Fine","year":"2007","journal-title":"Adv Anat Pathol"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.humpath.2018.05.005","article-title":"Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases","volume":"79","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"issue":"3, Suppl","key":"R18-20250615","first-page":"100090","article-title":"Pathological, clinical and molecular characterization of large cell neuroendocrine carcinoma (LCNEC) of the urinary tract","volume":"103","author":"Gandhi","year":"2023","journal-title":"Laboratory Investigation"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","article-title":"The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J Urol"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/iju.12729","article-title":"Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder","volume":"22","author":"Kaushik","year":"2015","journal-title":"Int J Urol"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000366522","article-title":"Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder","volume":"94","author":"Eswara","year":"2015","journal-title":"Urol Int"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PAP.0000000000000309","article-title":"The Genitourinary Pathology Society Update on Classification of variant histologies, T1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing implications of urothelial cancers","volume":"28","author":"Comp\u00e9rat","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"152993","DOI":"10.1016\/j.prp.2020.152993","article-title":"Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56","volume":"216","author":"Chen","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/PAI.0000000000000824","article-title":"Insulinoma-associated protein 1 (INSM1) expression in small cell neuroendocrine carcinoma of the urinary tract","volume":"28","author":"Kim","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R27-20250615","first-page":"02830","article-title":"Identification of lineage-specific transcriptional factor-defined molecular subtypes in small cell bladder cancer","volume":"S0302-2838(23)","author":"Feng","year":"2023","journal-title":"Eur Urol"},{"key":"R28-20250615","first-page":"562","article-title":"Comprehensive profiling of neuroendocrine carcinomas of the bladder with expanded neuroendocrine markers ASCL1, NEUROD1, POU2F3, YAP1 and DLL3","volume":"102","author":"Akbulut","year":"2022","journal-title":"Laboratory Investigation"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/386852a0","article-title":"An achaete-scute homologue essential for neuroendocrine differentiation in the lung","volume":"386","author":"Borges","year":"1997","journal-title":"Nature"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"21160","DOI":"10.1074\/jbc.M708692200","article-title":"Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung","volume":"283","author":"Neptune","year":"2008","journal-title":"J Biol Chem"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jtho.2022.06.004","article-title":"POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC","volume":"17","author":"Baine","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R34-20250615","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"djw122","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"3, Suppl","key":"R36-20250615","first-page":"S680","article-title":"The Prognostic significance of stem cell-like marker PLCG2 and novel neuroendocrine markers in bladder neuroendocrine carcinomas","volume":"103","author":"Akbulut","year":"2023","journal-title":"Laboratory Investigation"},{"key":"R37-20250615","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"R38-20250615","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","article-title":"Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile","volume":"4","author":"Hoffman-Censits","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R39-20250615","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","article-title":"High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins","volume":"7","author":"Zheng","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R40-20250615","first-page":"540","article-title":"Comprehensive molecular characterization of muscle-invasive bladder","volume":"171","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"R41-20250615","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"key":"R42-20250615","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"R43-20250615","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","article-title":"Molecular characterization of neuroendocrine-like bladder cancer","volume":"25","author":"Batista da Costa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"R44-20250615","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1200\/JCO.2021.39.15_suppl.4526","article-title":"Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): the MSKCC experience","volume":"39","author":"Guercio","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"R45-20250615","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/his.14707","article-title":"Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series","volume":"81","author":"Gopalan","year":"2022","journal-title":"Histopathology"},{"key":"R46-20250615","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R47-20250615","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"R48-20250615","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/j.clgc.2019.03.010","article-title":"Prognostic variables in patients with non-metastatic small-cell neuroendocrine carcinoma of the bladder: a population-based study","volume":"17","author":"Cattrini","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"R49-20250615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","article-title":"Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center","volume":"64","author":"Lynch","year":"2013","journal-title":"Eur Urol"},{"key":"R50-20250615","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"R51-20250615","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R52-20250615","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R53-20250615","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"R54-20250615","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"R55-20250615","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"R56-20250615","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","article-title":"PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: Concordance among 3 commonly used and commercially available antibodies","volume":"43","author":"Reis","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R57-20250615","doi-asserted-by":"crossref","first-page":"2532518","DOI":"10.1155\/2019\/2532518","article-title":"Immune exclusion is frequent in small-cell carcinoma of the bladder","volume":"2019","author":"Mandelkow","year":"2019","journal-title":"Dis Markers"},{"key":"R59-20250615","first-page":"395","article-title":"CD274 (PD-L1) copy number changes (gain) & response to immune checkpoint blockade therapy in carcinomas of the urinary tract. bladder","volume":"7","author":"Gupta","year":"2021","journal-title":"Cancer"},{"key":"R60-20250615","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"R61-20250615","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R62-20250615","doi-asserted-by":"crossref","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"key":"R63-20250615","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R64-20250615","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/1078-0432.CCR-18-1278","article-title":"Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target","volume":"25","author":"Koshkin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R65-20250615","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncologist"},{"key":"R66-20250615","doi-asserted-by":"crossref","first-page":"e0240973","DOI":"10.1371\/journal.pone.0240973","article-title":"The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy","volume":"15","author":"Tendler","year":"2020","journal-title":"PLoS One"},{"key":"R67-20250615","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2147\/OTT.S244860","article-title":"The Role of DLLs in cancer: a novel therapeutic target","volume":"13","author":"Xiu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R69-20250615","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.humpath.2020.11.014","article-title":"Well-differentiated neuroendocrine tumors of the lower urinary tract: Biologic behavior of a rare entity","volume":"109","author":"Rodriguez Pena","year":"2021","journal-title":"Hum Pathol"},{"key":"R70-20250615","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/PAS.0b013e318293d83c","article-title":"Identification of succinate dehydrogenase-deficient bladder paragangliomas","volume":"37","author":"Mason","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R71-20250615","doi-asserted-by":"crossref","first-page":"167 e13","DOI":"10.1016\/j.urolonc.2014.11.017","article-title":"Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes","volume":"33","author":"Martucci","year":"2015","journal-title":"Urol Oncol"},{"key":"R72-20250615","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000000534","article-title":"Urinary bladder paragangliomas: how immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations","volume":"39","author":"Giubellino","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R73-20250615","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.prp.2014.10.009","article-title":"Malignant paraganglioma of the bladder: a case report and review of the literature","volume":"211","author":"Quist","year":"2015","journal-title":"Pathol Res Pract"}],"container-title":["Advances in Anatomic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0000000000000433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:02:24Z","timestamp":1750003344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0000000000000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pap.0000000000000433","relation":{},"ISSN":["1072-4109"],"issn-type":[{"value":"1072-4109","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}